Adding Dosing Of Plasmid Encoding P62/Sqstm1 To Gemcitabine Chemotherapy May Provide Clinical Benefits To Patients With Platinum-Resistant Ovarian Cancer

Here we report the first intermediate analysis of a randomized prospective multi-center clinical study aimed to evaluate safety and efficacy of p62/SQTM1-encoding plasmid applied as an adjuvant to chemotherapy in patients with advanced platinum-resistant ovarian cancer. Previously we reported that the p62-plasmid reduces chronic inflammation, changes the tumor microenvironment, and increases the number of tumor-infiltrating lymphocytes. In a phase I/IIa study in patients with refractory solid tumors, the plasmid demonstrated high degree of safety and preliminary indications of efficacy.